



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

From Maturity to Value-Added Innovation

Citation for published version:

Mittra, J, Tait, J & Wield, D 2011, 'From Maturity to Value-Added Innovation: Lessons from the Pharmaceutical and Agro-Biotechnology Industries', *Trends in biotechnology*, vol. 29, no. 3, pp. 105-109. <https://doi.org/10.1016/j.tibtech.2010.11.004>

Digital Object Identifier (DOI):

[10.1016/j.tibtech.2010.11.004](https://doi.org/10.1016/j.tibtech.2010.11.004)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Trends in biotechnology

Publisher Rights Statement:

© Mittra, J., Tait, J. and Wield, D. (2011). From maturity to value-added innovation: lessons from the pharmaceutical and agro-biotechnology industries. *Trends in Biotechnology*, 29(3), pp. 105-109. doi: 10.1016/j.tibtech.2010.11.004.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



© Mitra, J., Tait, J. and Wield, D. (2011). From maturity to value-added innovation: lessons from the pharmaceutical and agro-biotechnology industries. Trends in Biotechnology, 29(3), pp. 105-109. doi: 10.1016/j.tibtech.2010.11.004.

From maturity to value-added innovation: lessons from the pharmaceutical and agro-biotechnology industries

James Mitra, David Wield & Joyce Tait

ESRC Innogen Centre, Old Surgeons' Hall, High School Yards, University of Edinburgh, EH1 1LZ

Corresponding author: Mitra, J. (James.Mitra@ed.ac.uk).

1 **Abstract:**

2 The pharmaceutical and agro-biotechnology industries have been confronted both by
3 dwindling product pipelines and rapid developments in life sciences, thus demanding a
4 strategic rethinking of conventional R&D. Despite offering both industries a solution to
5 the pipeline problem, the life sciences have also brought new and complex regulatory
6 challenges for multi-national firms. In this paper, we comment on these industries'
7 response to the life science trajectory in the context of maturing conventional small-
8 molecule product pipelines and routes to market. The challenges of managing transition
9 from maturity to a new high-value added innovation model are addressed. Further, we
10 argue that regulation has played a critical role in shaping the innovation systems of both
11 industries and, as such, we reflect on potentially useful changes to the current regulatory
12 system.

13

Introduction to the new life science industries

The new molecular life sciences have transformed a range of R&D-driven industries over the past couple of decades, particularly in pharmaceuticals and agriculture. Both industries are susceptible to “technological shocks” as new scientific knowledge and path-breaking technologies broaden the spectrum of options for R&D and strategic management. The complexity of the life sciences, and the different implications of biotechnology and genomics for various parts of the R&D process, have created what are now highly distributed innovation systems and company networks in both sectors [1-3]. Firm strategy is shaped by robust, though ever-changing, multi-layered and sometimes cumbersome regulatory systems that are located outside the core innovation system, but which continue to influence innovation at all times [4]. The success of multi-national companies depends on a continuous flow of new, innovative products with clear routes to market and established, well-understood value systems. In pharmaceuticals, these have traditionally been small-molecule blockbuster products in core therapeutic franchises. Similarly, until the early 1990s, the dominant innovation model in the agricultural sector was global commodity crops. In both industries, new technologies, such as high-throughput screening and combinatorial chemistry, were embraced enthusiastically and brought product and process advances in the identification, validation and formulation of new chemicals.

Rapid developments in the life sciences in the late 1980s and early 1990s brought new opportunities and challenges for both industries, and continue to do so today. Just as conventional product pipelines began to reach maturity, the new life sciences offered hope of developing radically different types of product and markets to displace prior

innovation strategies. For the pharmaceutical industry, recombinant proteins in the 1980s, monoclonal antibodies in the 1990s, and more recently stem cells, emerged as potential alternatives to blockbuster small molecule drugs. Similarly, in the late 1980s GM crops presented the agro-chemical industry with a radically new product portfolio that was disruptive to its prevailing R&D strategy. However, the life sciences also brought new competition for incumbent firms as smaller biotechnology companies with unique knowledge and expertise emerged. The path-breaking nature of the new technologies and products, many with unknown risk profiles and without established routes to market, engender new regulatory hurdles that increase the cost of R&D and generate uncertainty.

Our aim is to explore the evolution of the pharmaceutical and agro-biotechnology industries in the context of emerging life science innovation and new regulatory systems, and suggest key lessons for future governance. We use the term agro-biotechnology in this article to refer specifically to those agrochemical companies that linked with seed companies to produce GM crops. We highlight the opportunities and challenges of managing transition from maturity to a new high-value-added innovation model subject to high regulatory hurdles and hope to spur a broader discussion about the systemic aspects of R&D-driven industries and the role of regulation in shaping innovation.

From maturity to value-added innovation: challenges and opportunities

Developments in the life sciences have reshaped the pharmaceutical and agro-biotechnological industries. During the 1980s and early 1990s, the largest multinational chemical firms had a relatively integrated and complementary R&D strategy. Indeed, some had both health and agriculture divisions. This period of innovative activity was

characterised by a series of mergers and acquisitions as multinationals sought “buy-in” to new technology platforms [5].

However, this “combination strategy” ended around the late 1990s. The two sectors separated their capabilities and pursued autonomous strategies of innovation through both merger and acquisition (M&A) activities and strategic alliances. It became clear to senior managers that synergy between agriculture and pharmaceuticals at the discovery-level was profitable only when both sectors were primarily interested in the source of chemical novelty, but not in the “gene” area [5,6]. Functional genomics could have benefited both sectors in their search for novel and commercially viable chemicals, but disparities in profit margins [7] and technological and economic differences [8] between the sectors did not make for positive synergies.

Responding to the “problem of maturity”

In the early 1990s, both sectors struggled as conventional chemical-based products reached maturity and R&D pipelines narrowed. By “maturity”, we mean molecules had already been developed for easy targets and were now off-patent, so no longer generating large profits, and industry was concerned about the long-term sustainability of conventional blockbuster R&D models. Both sectors searched for new R&D options. In agriculture, strategic planning focused on ‘a combination of chemical and biotechnology developments with varying degrees of synergistic interaction’ [9,10]. Companies embraced diversity in technological development [11]. As product pipelines matured, three distinct company strategies emerged to exploit the new life science trajectory (Box

1)

Innovation strategies are cumulatively dependent on a company's past history [12,13], and the resources and 'dynamic capabilities' of a firm also influence its patterns of innovation [13]. The innovation strategies of agro-biotechnology companies in the 1980s and 1990s varied, depending on their existing strengths in product development and technology trajectories along with their overall vision for the future. GM crops were a disruptive technology for most multi-national agro-biotechnology companies still benefiting from patented agro-chemical products, but were attractive to firms that had reached the limits of small molecule chemical innovation and whose existing product range had reached a critical level of maturity.

In pharmaceuticals, the maturity problem and the desire to move to high-value-added biotechnology-based products was also a driver of organisational change and restructuring. Traditionally, pharmaceutical R&D was a serendipitous activity in which chemical compounds were randomly screened and tested on known disease targets. Lead molecules were then optimised by medicinal chemists to produce lead candidates for further development. In the 1980s and 1990s, advances in molecular biology, synthetic chemistry and screening technologies reshaped this R&D process [14] and created economies of scale and scope [15]. The emergence of potentially transformative life science technologies led to major industry restructuring, through internal reorganisation and merger, acquisition and strategic alliance activity [2,16,17]. (Box 1). Firms now coordinate an increasingly diverse range of R&D capabilities alongside the "normal" processes of organic growth [18]. However, despite the promises and strategic visions presented by the life sciences, various factors challenge large firms' dominance in therapeutic innovation (Box 2).

Together, these challenges, amongst others [24], continue to shape the evolution of the pharmaceutical sector and strategic management of R&D within individual firms, with new R&D models and product development strategies emerging. For example, GSK developed Centers of Excellence for Drug Discovery in 2000, leading to its current decentralised R&D Hub structure [25,14], and most multinationals exploit public-private partnerships in both research and development. A good example of this is Pfizer's current investment in Scotland's Translational Medicine Research Collaboration (TMRC), which is focused on the identification and validation of novel biomarkers for drug development.

Both the pharmaceutical and agro-biotechnology industries have been forced to confront the challenges and opportunities of the molecular life science paradigm in the context of maturity and drying-up of conventional product pipelines. For the pharmaceutical industry, life science investment and attendant organisational restructuring has been primarily a response to the challenges of therapeutic innovation, rather than a revolutionary, pro-active attempt to fully embrace a life science-based innovation trajectory. Innovation spending in agro-biotechnology has moved towards GM seed technology, with total agro-biotechnology R&D expected to equal agrochemicals in 2009 [26].

Our research on both the agricultural and pharmaceutical industries has shown that multi-nationals do not always share common objectives and strategies; rather, strategy is an evolutionary process based on firms' unique histories, internal competencies and routines, market position and future expectation [2,9,14] The long-lead times in pharmaceutical and agro-biotechnology R&D mean that the precise benefits of any restructuring initiative and implantation of new strategy take time to emerge.

Nevertheless, product innovation and company strategy is also determined by the regulatory environment and it is to this important aspect that we now turn.

Regulation and its impact on innovation strategy and product development

Regulation has perhaps the most significant impact on R&D-driven industries, such as pharmaceuticals and agro-biotechnology, and partly explains the long product lead times that distinguish these industries from most others, although even without formal regulation firms would still need to invest time and resource to establishing product safety. Nevertheless, changes in standards for safety and efficacy do have time/cost implications for industry [27]. The most significant and damaging effect of regulation in agro-biotechnology has been to increase costs, over conventional non GM varieties, by approximately 0.5 to 13.5 million USD [28]. We argue that regulation is the dominant shaper of both the innovation system and markets for innovative products in pharmaceuticals and agro-biotechnology. Specifically, it can constrain life science innovations through the complex, expensive and lengthy requirements imposed on developers of new drugs or pesticides. It has been recently suggested that clinical trials required by European regulators to compare biosimilar products with corresponding biologic brands are unnecessary and may impede the development of biosimilars of more complicated biologics [31]. Although this particular example is focused on biosimilars rather than novel biologics, it does highlight how regulation impacts on innovation. The nature of the regulatory system for any given product can dictate the type of firms able to develop such products [4].

To highlight the role and influence of regulation on both sectors, we look briefly at the regulation of two “disruptive technologies”; namely, GM crops in the agrobiotechnology sector and stem cells/regenerative medicine in the pharmaceutical sector. Specifically, the systemic interactions of regulation and innovation for these two sectors and technology platforms are highlighted. Box 3 provides a background summary of the specificity of life science regulation.

Path-breaking Versus Path-Dependent Products and Regulation

Scientific knowledge and technological advances in biotechnology have led to radically new path-breaking products in health and agriculture, including GM crops and stem-cell-based therapies. In both cases, regulation was considered crucial, but with no precedent for establishing a robust governance framework. In cases of new technologies, one can either look for existing regulatory regimes within which to place new product ranges, or design new path-breaking regulatory frameworks to meet the specific properties of the new technology. Based on our research on innovation and governance in life sciences [28-30], we consider it important to question the relationship between the emergence of path-breaking innovations and the putative need for path-breaking regulatory systems.

Path-breaking innovations do not always require novel regulatory mechanisms. GM crops were a path-breaking technology, and the agro-biotechnology industry expected that they would be disruptive and move the sector onto a new high value-added innovation model, but it was not clear for quite some time after companies had invested heavily in their development what the nature of the regulatory regime would be. While

companies can cope with radical changes to their innovation systems, when these challenges are coupled with uncertainty in markets and regulatory regimes that are outwith their control, disruption to the entire sector can be magnified [4].

Innovation that is “path-breaking” for one company or sector may of course be “path-dependent” for another. For example, it was not inevitable that GM crops would be developed and marketed only by the agro-biotechnology industry, for which they were clearly path-breaking; GM crops disrupted the prevailing innovation model, simultaneously impacting company R&D strategy (i.e. requiring a shift from chemistry- to biology-based development and production systems), markets (i.e. seed markets are very different from pesticide markets), and regulatory systems. In the 1980s and early 1990s, it was equally likely that food and seed companies would develop the technology. For these companies, the technology was path-dependent [4,30].

A complex set of interactions between policymakers at European, U.S. and international levels, as well as among the agro-biotechnology, food production and distribution, and seed industry sectors, contributed to the overall framing of GM. It would have been beneficial to operationalise a rule that guided policymakers to adopt the regulatory system that applied to the industry sector for which the technology was path-dependent; in this case the seed companies. The regulation of GM crop varieties would have been a lot easier (perhaps regulated under plant breeders’ rights) if the key initial developers had been the seed firms. This path-dependent regulatory approach may have made a significant difference to the direction of innovation in GM crops today and also to the public perception of the technology in Europe.

This analysis may also apply to the pharmaceutical sector in the case of stem cells and regenerative medicine. Stem cells, like GM crops, are potentially highly disruptive of prevailing pharmaceutical R&D systems, markets and regulatory systems. They require modification of company R&D strategies, moving from small-molecule innovation to complex biologics, and markets, which are very different to conventional blockbuster drug markets (they have much smaller patent populations and delivery of the product to the patient can be far more complex and expensive). The nature of the regulatory requirements will also determine whether such products are developed by conventional multi-national drug companies or the smaller tissue engineering firms. In parallel with the example of GM crops, stem cells would be path-breaking for pharmaceutical multinationals, but path-dependent for smaller tissue engineering companies. Comparison with GM crops would suggest that if regulation of stem cells could be framed so as to be path-dependent for the smaller companies, we might see faster and more innovative development and uptake of novel therapies. However, if the regulatory framework continues to align more closely with the sector to which the technology is path-breaking (in this case multinational pharmaceutical firms), which appears to be the case with the Advanced Therapies Regulation in Europe [<http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF>], we could see delays in the development of therapies and few small, innovative companies independently developing stem cell products. Whilst it is of course essential that stem cells and regenerative medicine products meet the key requirements of safety and efficacy, the question is whether the conventional regulations that apply to small molecule blockbuster products, and more conventional biologics, are appropriate for stem

cells; especially when they may be a barrier to innovation. Whilst there are certainly many myths and uncertainties about the regulatory gaps and barriers to regenerative medicine [32], there is yet no clear route to market for many of the small companies developing the technology and regulatory guidelines can be vague and ambiguous. Lessons from the regulation of GM crops may help us to develop regulatory processes for stem cells that encourage, rather than impede, those companies best placed to innovate in this area.

Conclusion: key lessons for new “smart” approaches to regulation

Regulatory systems tend to evolve incrementally over long time periods, which make them susceptible to becoming inflexible and out-of-step with the latest innovations and technologies. Furthermore, because regulation builds up in this way, it can become so complex that modifications to one set of regulations have unforeseen consequences for other parts of the regulatory system and for the innovation community. However, *de novo* creation of path-breaking regulation for path-breaking technology also poses difficulties and challenges and could just as easily discourage innovation as encourage it.

From our extensive research that has explored innovation and regulation interactions in the pharmaceutical and agro-biotechnology sectors [2-6; 9, 10, 14, 30] we consider there to be a number of key lessons for better governance of innovative life science technologies, such as GM crops and stem cells [Box 4].

The life sciences continue to be of high strategic importance to both developed and emerging economies and shape many innovative industries. But life science innovation is

largely dominated by a relatively small number of multinational companies, and regulatory systems often serve to maintain the status quo. Regulation is an insurmountable barrier to many small start-up companies with innovative ideas that challenge prevailing orthodoxy. Whilst it would of course be inappropriate to lower safety and efficacy standards for life science-based products, the development of a smarter approach to regulation, which we have outlined, could bring about a more favourable climate for innovation.

Acknowledgements

The authors would like to acknowledge the support of the ESRC Innogen Centre (Grant Number RES-145-28-0002) in providing the funds for the various research projects on which the opinions stated in this article are based. We would also like to thank the editor and two anonymous referees for their valuable comments.

References

1. Chiesa, V. & Toletti, G. (2004) 'Network of Collaborations for Innovation: The Case of Biotechnology', *Technology Analysis and Strategic Management*, 16 (1), pp. 73-96
2. Mitra, J (2007) 'Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour Large Firms', *Technology Analysis and Strategic Management*, 19 (3), pp. 279-301
3. Mitra, J. & R. Williams (2007) 'Editorial: Evolution of the Life Science Industries', *Technology Analysis and Strategic Management*, 19 (3), pp 251-255
4. Tait, J. (2007) Systemic interactions in life science innovation, *Technology Analysis and Strategic Management*, 19 (3), pp. 257-277
5. Tait, J. et al (2001) *Policy Influences on Technology for Agriculture: Chemicals, Biotechnology and Seeds Final Report*, Policy Influences on Technology for Agriculture (PITA), Report to European Commission Targeted Socio-Economic Research

- Programme (TSER), Project no. SOE1/CT97/1068. Available at:
<http://www.technology.open.ac.uk/cts/pita/>
6. Chataway, J. et al (2006). 'The governance of agro- and pharmaceutical biotechnology innovation: public policy and industrial strategy', *Technology Analysis and Strategic Management*, 18(2), pp. 169–185.
 7. Niiler, E. (2000) 'Demise of the Life Science Company Begins', *Nature Biotechnology*, 18, p. 14
 8. Walsh, V., and Lodorfos, G., (2002), "Technological and Organisational Innovation in Chemicals and Related Products", *Technology Analysis and Strategic Management*, 14 (3)., pp. 273-298.
 9. Chataway, J. et al (2004) 'Understanding Company R&D Strategieis in Agro-Biotechnology: Trajectories and Blind Spots', *Research Policy*, 33, pp. 1041-1057
 10. Tait, J. & J. Chataway (2007) 'The Governance of Corporations, Technological Change, and Risk: Examining Industrial Perspectives on the Development of Genetically Modified Crops', *Environment and Planning C: Government and Policy*, 25, pp. 21-37
 11. Granstrand, O. P. Patel & K. Pavitt (1997) 'Multi-technology Corporations: Why they have "Distributed" rather than "Distinctive Core" Competences', *California Management Review*, 39 (4), pp. 8-25
 12. Dosi, G et al (1998) *Technological Change and Economic Theory*, (London: Pinter)
 13. Teece, D.J., Pisano, G., and Schuen, A. (1997) Dynamic capabilities and strategic management, *Strategic Management Journal*, 18 (7), pp. 509-530
 14. Mittra, J. (2008) 'Impact of the Life Sciences on Organisation and Management of R&D in Large Pharmaceutical Firms', *Int. J. Biotechnology*, 10 (5), pp. 416-440
 15. Nightingale, P. (2000) Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D, *Industrial and Corporate Change*, 9, 2000, pp. 315-359
 16. Drews, J. (2000) Drug discovery: a historical perspective, *Science*, 287, pp. 1960-1964
 17. Cambrosio, A., Keating, P., and Mogoutov, A. (2004) Mapping collaborative work and innovation in biomedicine, *Social Studies of Science*, 34 (3), pp. 325-364
 18. Coombs, R., and Metcalfe, S. (2002) Innovation in pharmaceuticals: perspectives on the co-ordination, combination and creation of capabilities, *Technology Analysis and Strategic Management*, 14 (3), pp. 261-271

19. Drews, J. and Ryser, S. (1996) Innovation deficit in the pharmaceutical industry, *Drug Information Journal*, 30, pp. 97-108
20. Horrobin, D. F. (2001) Realism in drug discovery – could Cassandra be right? *Nature Biotechnology*, 19, pp. 1099-1100
21. Horig, H., and Pullman, W. (2004) From bench to clinic and back: perspective on the first 1st IQPC Translational Research Conference, *Journal of Translational Medicine*, 2 (44)
22. Pardridge, W, M. (2003) ‘Translational Science: What is it and Why is it so Important?’ *Drug Discovery Today*, 18, pp. 813-815
23. Dimasi, J.A., & H.G. Grabowski (2007) ‘The Cost of Biopharmaceutical R&D: Is Biotech Different?’, *Managerial and Decision Economics*, 28 (4/5), pp. 469-479
24. Tait, J. & Mittra, J. (2004) ‘Industry Challenges’, *Chemistry and Industry*, 6 December, 2004, No. 23, p. 24
25. Nature Biotechnology (2001) GlaxoSmithKline presents a biotech façade, *Nature Biotechnology*, 19 April, 2001
26. Wield, D et al (2010) ‘Issues in the Political Economy of Agricultural Biotechnology’, *Journal of Agrarian Change*, 10, 3, pp. 342-366
27. Milne, C. P. (2008) ‘Fixing the Paradigm for Biopharmaceuticals R&D: Where to Start?’ *International Journal of Biotechnology*, 10 (5), pp. 404-415
28. Tait, J. et al (2008) *Health Biotechnology to 2030*. Report to OECD International Futures Project, “The Bio-Economy to 2030: Designing a Policy Agenda”, OECD, Paris, pp.51; <http://www.oecd.org/dataoecd/12/10/40922867.pdf>
29. Tait, J., & R. Williams (1999) ‘Policy Approaches to Research and Development: Foresight, Framework and Competitiveness’, *Science and Public Policy*, 26, pp. 101-112
30. Tait, J. et al (2006) ‘Governance, Policy and Industry Strategies: Agro-biotechnology and Pharmaceuticals’. In eds. M. Mazzucato and G. Dosi *Knowledge Accumulation and Industry Evolution*, Cambridge University Press, pp. 378-401
31. Schellekens, H. & E. Moors (2010) ‘Clinical Comparability and European Biosimilar Regulations’, *Nature Biotechnology*, 28 (1), pp. 28-31
32. Bravery, C. A (2010) ‘Regulating Interface Science Healthcare Products: Myths and Uncertainties’, *Journal of the Royal Society*, 7 (53), pp. 789-795

Box 1. Agro-biotechnology company strategies

Distinct strategies were employed by leading agro-biotechnology companies. These strategies were conceived in response to external pressures, including low farm commodity prices and income; erosion of profit margins; more aggressive competition as a result of agribusiness restructuring; and the emergence of new technologies, such as genetic modification and molecular marker technologies, which challenged conventional farming practice. The narrowing of conventional chemical pipelines also drove this need for a new strategic vision. Companies employed these different strategies to respond to maturity and pressures in the innovation environment.

“Buying the route to market”

Monsanto and Dupont both invested heavily in building the GM technology base for the world’s major commodity markets: corn, soya and cotton. Moving from selling agrochemicals to selling seeds required a new marketing strategy, and both companies invested large sums in acquiring seed companies.

“Collaboration along the route to market”

AgrEvo, Zeneca, Novartis, Rhone Poulenc and Dow also invested significantly in building a GM technology base, but they focused more on collaboration with seed companies rather than on outright purchases. This was a more incremental strategy.

“Jumping on the bandwagon”

387 BASF and Bayer were intentionally several years behind other agro-biotechnology
388 companies in investing in GM technology, preferring to wait and to benefit from the
389 experience of other companies.

390

Box 2. Key challenges facing the pharmaceutical industry (1990s – present day)

1. Decline in R&D productivity despite increases in R&D investment. The problem of product maturity coupled with a productivity crisis led to a perception of an “innovation deficit” that continues today[19]. Since 1996, the number of small molecule chemicals approved by regulators has been in decline and the number of new active compounds discovered has remained relatively constant. Companies are simply not generating enough new compounds in-house for sustainable growth [20].

2. High attrition rate of compounds, particularly during Phase II clinical trials. Lack of demonstrable safety and efficacy has been the principal cause of attrition, which is partly why companies now experiment with new “translational sciences” [21,22], particularly those centred on the identification and validation of novel biomarkers.

3. Rising overall costs of drug discovery owing to the need for new, experimental methodological approaches to drug discovery and development, the increasing internationalisation of research and its competitive environment, and increasing demands of regulators and healthcare providers. In 2007, the cost for a large pharmaceutical firm to bring one product to market was estimated to be \$800 million USD [23].

4. Some early biotechnology firms were successful in transforming themselves into large multinationals (Amgen, Genzyme, Genentech and Geron, for example); but later growth in biotechnology has been slow, and the chances of a small, innovative biotechnology firm becoming a large, independent company today now appears bleak given the high regulatory barriers to entry.

415

416 **5.** There has been some, small increases in **partnerships between public and private**
417 **institutes** to pool information and attempt delivery of niche products, including orphan
418 products and products for developing countries, such as vaccines. Nevertheless, the
419 dominant model continues to rely on “blockbuster drugs” rather than targeted drugs for
420 niche markets. Large firms have always needed to target three or four key blockbuster
421 markets to remain competitive and sustain revenue growth. Despite the life science
422 promise of radically new therapies for smaller populations (such as stem cell treatments
423 and personalised medicines), multinational pharmaceutical firms did not seek to
424 completely transform themselves into biotechnology companies; this is in contrast to
425 some of the agro-biotechnology companies like Monsanto. Indeed, there has not yet been
426 a pharmaceutical equivalent to Monsanto.

427

Box 3: The nature of regulation in the life sciences

Whilst it is obvious that regulation impacts product development, we suggest that the impact of regulation is much more far reaching than just ensuring goods are safe, effective and high-quality – [28]. It determines overall company strategy, the types of firm that will succeed in bringing products to market, and the structural dynamics of the sector as a whole. For example, if we compare the lightly regulated Information and Communication Technologies ICT sector with the heavily regulated life sciences, the former has a much greater turnover of products and capabilities arising from technological innovation. In ICT, small start-up companies can quickly become major players by developing innovations that challenge the status quo. Most candidates for product development in the health and agricultural sectors will fail (only one out of approximately 200,000 molecules initially screened will make it to product launch); therefore, innovation in life sciences appears far more linear than industries such as ICT [29]. Life science innovation is dominated by a small group of multinationals, which we argue is partly due to the fact that the regulatory system poses an insurmountable barrier for many new entrants with innovations that threaten to disrupt the status quo.

The markets for life science products are also different from most other industries, inasmuch as few are marketed directly to consumers. Pesticides and GM crops are sold to farmers, and new medicinal products are mainly sold to health services [10]. The unique combination of regulation and markets for life sciences has therefore had major impacts on the structural dynamics and strategic management of both the pharmaceutical and agro-biotechnology sectors.

451

452 **Box 4 : Key lessons for good governance of the life sciences**

453 (1) Regulatory initiatives can have significant, rapid and positive influences on the
454 innovation system. Such insights on successes should be used as exemplars when
455 designing or re-designing regulatory systems for new innovations.

456 (2) Regulations that may be appropriate for one policy area can have unexpected
457 and/or negative impacts when applied to other areas. Use of blockbuster drug
458 clinical trials systems when applied to stem cells could be a major constraint, with
459 adaptations to mechanisms such as the ‘hospital exemption route’ for the
460 development of therapies for named patients perhaps a better way to encourage
461 innovation in this sector. This problem is more likely and significant if regulators
462 are not sufficiently aware of the potentially useful, but also vulnerable, new
463 science, products and processes in development.

464 (3) A regulatory policy that is *enabling* in that it encourages positive change in
465 industry strategies and appropriately *discriminates* among products on the basis of
466 socially and economically relevant criteria, will generally be more effective and
467 efficient than a policy that is *indiscriminate* and seeks to *constrain* what it
468 considered undesirable behaviour.

469 (4) The *enabling* criterion affects the rapidity with which a particular regulatory
470 policy can exert influence, while the range, scope and appropriateness of its
471 *discrimination* among products and processes will determine its effectiveness in
472 guiding product development in desired directions.

- 473 (5) Path-breaking regulation for path-breaking technology should not be the norm;
474 rather, it should be the last resort once all other options have been exhausted.
475 Other options might include, for example, a focus on ‘substantial equivalence’. If
476 the new technology or product is substantially equivalent to an existing product,
477 path-breaking regulation should not be necessary. Existing regulatory frameworks
478 ought to be sufficient.
- 479 (6) Finally, in considering which regulatory precedent is most appropriate for a new
480 innovative technology, a useful approach would be to first consider the regulatory
481 system in operation for the industry sector for which the innovation is path-
482 dependent, rather than for the one for which it is path-breaking. This would
483 ensure the sector better positioned to quickly take forward the product to market
484 is encouraged to do so.